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Abstract 
Purpose of review 
Infection with Chlamydia trachomatis in pregnancy is linked to increased risk of miscarriage, stillbirth, 
and preterm birth. Currently, PCR or DNA-based tests are the gold standard when detecting the infection; 
however, they are costly and require access to specialist equipment. The aim of this systematic review 
was to assess the accuracy of available tests to detect infection in an asymptomatic pregnant population. 
Recent findings 
There was evidence of the superior accuracy of nucleic acid amplification tests to cell culture in non-
pregnant asymptomatic women; however, there are multiple commercial nucleic acid amplification tests 
with varying sensitivities and specificities. There is a gap in current literature on accuracy studies in an 
asymptomatic pregnant population, particularly within routine antenatal settings. 
Summary 
There is a need for a point-of-care test for Chlamydia in pregnancy. Future test accuracy studies for this 
population should aim to use a universally established reference standard. Further research should 
provide relevant evidence to guide practice. 
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Introduction 
Chlamydia trachomatis, commonly referred to as chlamydia, is the most common sexually transmitted 
infection (STI) worldwide with 105.7 million cases [1]. Of this, the largest proportion is within south and 
southeast Asia, and sub-Saharan Africa [2]. Early detection is a key in order to prevent complications, 
such as cervicitis, urethritis, and pelvic inflammatory disease; however, 70–80% of infected women are 
asymptomatic [3]. The infection is most commonly transmitted through sexual intercourse and can also 
be passed from mother to baby in utero or during birth. Untreated infections of pregnant women have 
been linked to newborn blindness [2], miscarriage, stillbirth, and preterm birth. The treatment of 
chlamydial infections with antibiotics such as erythromycin has been shown to be efficacious in 
preventing these adverse outcomes, as well as the transmission to the newborn. nTherefore, the 
identification of a suitable screening test is important in order to isolate C. trachomatis within an 
asymptomatic pregnant population and provide treatment [4]. 
The major obstacle in controlling and preventing of Chlamydia infection within resource-limited settings 
is the unavailability of reliable, low-cost, point of care tests (POCTs) which detect and treat the infection 
during the same visit [5]. Current reviews assessing the accuracy of tests detecting C. trachomatis identify 
PCR or DNA-based tests as the best performing tests; however, their study populations were not specific 
to a pregnantpopulation[6,7].Theaimof our work was to review and synthesize the accuracy of  tests used 
in an asymptomatic pregnant population to detect infections with C. trachomatis 
KEY POINTS 
 There is evidence for application of NAAT-based testing in an asymptomatic pregnant population.  
 There are multiple commercial NAATs available with varying sensitivities and specificities. 
 Future test accuracy studies for this population should aim to use a universally established reference 
standard. 
 
MATERIALS AND METHODS 
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The search strategy was run in EMBASE, MEDLINE (OVID), SCOPUS, and Web of Science with no 
language restrictions. A supplementary search was also conducted in LILACS and GreyOpen, a database 
with grey literature. The search was run from inception up to February 2015, updated in February 2016 
and June 2017. No time limit was included in the search filter. 
Study selection 
Two independent reviewers (S.V.S. and S.S.) screened references and then the full texts of potentially 
relevant articles of the initial search (up to February 2015). The reference screening for the two updates 
was done only by one reviewer (S.V.S.). The study had to meet the following eligibility criteria: recruit 
pregnant women without symptoms of Chlamydia, carrying a single fetus with no history of preterm 
delivery. We included studies where the data were presented as true positive, true negative, false 
negative, false positive, or as sensitivity, specificity, positive predictive value, negative predictive value, 
and sample size. We excluded studies in which the pregnant population showed symptoms of Chlamydia. 
At each stage of the review process, the consensus was reached through a discussion. In the case of 
disagreement, the opinion of a third reviewer was sought (E.R.). 
Data extraction and study quality assessment 
Following data were extracted from the studies: characteristics of the study, e.g., study design, 
recruitment setting, inclusion/exclusion criteria, as well as information on the index and reference tests 
being compared. The information on the tests included specimen collection, storage, testing, and 
interpretation of the tests. The quality assessment was conducted by two reviewers (E.R. and S.V.S.) 
using the QUADAS-2 tool [8]. The study quality was assessed in four domains: patient selection, choice 
of the index test, choice of the reference standard, and the flow of patients through the study. The studies 
were classified as ‘low’, ‘high’, or ‘unclear’ for the level of risk of bias. The details of QUADAS-2 are 
included in the data extraction form (see SDC). Numeric data were imputed into the Review Manager 
(RevMan) software (version 5.1, Copenhagen; The Nordic Cochrane Centre, The Cochrane 
Collaboration, 2014). 
RESULTS 
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Characteristics of included studies 
We identified 12 studies evaluating accuracy of onsite tests to detect infections with C. trachomatis 
among pregnant women. The studies were published between 1986 and 2006 with no new studies 
identified within the last year. The studies evaluated a following tests: PCR, direct enzyme immunoassay 
(MicroTrak SYVA), direct immunofluorescence assay (MicroTrak SYVA), Chlamydiazyme (Abbott 
Laboratories), chlamydia immunoglobulin A (IgA) Rapid SeroTest ELISA (Savyon Diagnostics), Gen-
Probe PACE 2 (Gen Probe Inc AQ8 .), immunoglobulin G (IgG) level via immunofluorescence 
techniques, Papanicolaou smear, and wet mount gram stain (Table 1) [9–20]. Seven studies recruited 
women in antenatal care settings [9–15] and five women who were present at the clinic for termination of 
pregnancy [16,17–20]. The prevalence of the infection ranged from 2 to 87%. All studies except one [11] 
were carried out in high-income countries (Table 2) [9–20]. 
Quality assessment 
A total of 8 out of 12 included studies did not provide sufficient description of women’s enrolment 
(unclear risk of bias). The majority of the studies were assessed as a low risk of bias regarding 
implementation of the index test (Table 3) [9–20]. The risk of bias in 75% (9/12) of studies on the 
reference standard was considered as unclear due to insufficient information. The risk of bias for flow 
and timing was unclear in two studies [14,18] and high in one [19]. Women in five studies were recruited 
from termination clinics. Therefore, the concern regarding the applicability of population from those 
studies was considered as high. The applicability of index tests in most studies was good (low concern). 
The use of the cell culture as a reference standard due to change of diagnostic standards resulted in eight 
studies being labelled as an unclear concern of applicability for the reference standard. 
Cell culture as reference standard 
Nucleic acid amplification tests 
One study reported the sensitivity of the Gen-Probe PACE 2 assay to be 93.9% [confidence interval (CI) 
95% 79.8–99.3] and specificity 99.1% (CI 95% 96.7– 99.9). Another study assessed the accuracy of PCR 
(Ampl-Taq Polymerase) method in comparison to cell culture. The sensitivity of PCR was 77.8% (CI 
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95% 40.0–97.2) and specificity 99.2% (CI 95% 97.7– 99.8) [20]. Another study used a PCR method with 
plasmid primers had sensitivity 90.0% (CI 95% 78.2–96.7) and specificity 92.6% (CI 95% 82.1– 97.9) 
when compared with the Pathfinder [18].  
Enzyme-linked immunoassays  
Accuracy data for SYVA MicroTrak (Syva Company) [20] and Chlamydiazyme (Abbott Laboratories) 
[15] were reported in two separate studies. Chlamydiazyme had a higher sensitivity at 90.9% (CI 95% 
58.7–99.8) compared with SYVA Microtrak at 75% (CI 95% 42.8–94.5), but had a lower specificity at 
97.9% (CI 95% 92.6–99.7) compared with Microtrak’s 98.3% (CI 95% 96.5–99.3). 
Papanicolaou smear 
Two studies reported the accuracy of Papanicolaou smear test in comparison to cell culture. One study 
reported sensitivity and specificity to be 11.1% (CI 95% 28–48.25) and 98.1% (CI 95% 93.2–99.8), 
respectively; [11] whereas the other study reported it as 60.5% (CI 95% 44.4–75.0) and 56.4% (CI 95% 
50.1–62.6) [19]. 
Direct immunofluorescence assay 
One study reported SYVA MicroTrak’s direct immunofluorescence assay (DFA) technique [20] 
sensitivity and specificity as 81.3% (CI 95% 48.2–97.7) and 99.5% (CI 95% 98.2–99.9) respectively. 
Microimmunofluorescence 
Three different titres of cervical antibodies were visualized using microimmunofluorescence techniques 
in the same study [12]: IgA 8 or less, IgG 8 or less, and IgG 16 or less. The sensitivity of the titres was 
59.1% (CI 95% 36.4–79.3), 63.4% (CI 95% 40.7–82.8), 45.5% (CI 95% 24.4–67.8), respectively, 
accompanied by specificity of 95.3% (CI 95% 93.8– 96.5), 93.9% (CI 95% 92.3–95.3), and 98.4% (CI 
95% 97.4–99.1) respectively. 
Immunoperoxidase assay 
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One study detected serum IgG and IgA antibodies using a single serovar (L2) immunoperoxidase assay 
[17]. The two titres used were IgG 16 or less and IgA 8 or less. The sensitivity of IgG 16 or less as a titre 
was 95.2% (CI 95% 76.2–99.9) and specificity 43.4% (CI 95% 33.8–53.4). The sensitivity and specificity 
of IgA 8 or less titre were reported as 52.4% (CI 95% 29.8– 74.3) and 81.3% (CI 95% 72.4–88.1) 
respectively. 
Gen-probe PACE 2 as reference standard 
Wet mount gram stain 
Two studies reported data comparing Wet mount gram stain to Gen-Probe PACE 2 with varying results 
in sensitivities and specificities. One study reported a sensitivity of 91.4% (CI 95% 76.9–98.2), [9] 
whereas the other reported 86.7% (CI 95% 69.3–96.2) [10]. The specificities were calculated to be 18.0% 
(CI 95% 14.7–21.7) and 33.6% (CI 95% 28.3–39.1), respectively. 
PCR 
One study reported PCR technique to have a 100% (CI 95% 90.0–100) sensitivity and 98.3% (CI 95% 
96.8–99.3) specificity when compared with Gen-Probe PACE 2 [9].  
Other reference standards 
Enzyme-linked immunoassays vs. ligase chain reaction 
One study compared Clearview Chlamydia MF test which utilizes enzyme-linked immunoassays (EIA) 
techniques to detect Chlamydia, to ligase chain reaction but it used PCR as an arbiter. Sensitivity was low 
at 66.7% (CI 95% 44.7–84.4); however, specificity was 100% (CI 95% 99.0–100) [16]. 
Enzyme-linked immunoassays and direct immunofluorescence assay vs. PCR 
One study compared Chlamydia IgA Rapid SeroTest, which utilized an EIA technique, to Amplicor PCR 
and reported a sensitivity of 95.6% (CI 95% 78.1–99.9) and specificity of 93.1%(CI95%87.7–96.6).The 
same study compared Chlamydiazyme, a DFA technique, to the same reference standard of Amplicor 
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PCR and reported a sensitivity of 69.6% (CI 95% 47.1–86.8) and specificity of 97.2% (CI 95% 93.0–
99.2) [15]. 
 
DISCUSSION 
Gen-Probe PACE 2 had the highest sensitivity compared with cell culture out of all evaluated tests 
compared. PCR had the highest sensitivity compared with the Gen-Probe PACE 2. 
Strengths and limitations 
The search strategy was also designed in a systematic way using established, published filters to capture 
test accuracy studies [21]. The majority of the included studies had an unclear risk of bias concerning 
patient selection, where the risk of bias was labelled as unclear with respect to the index test and 
reference standard, it was mainly due to a lack of information about blinding of technicians.  
There were significant concerns over the applicability of the sample population as some studies recruited 
pregnant women who were presenting for termination of pregnancy, a higher risk population, potentially 
giving the tests an inflated accuracy compared with women presenting for routine antenatal care who are 
a lower risk population. The prevalence rates within the antenatal setting ranged from 2.04% to 13.8% 
and from 2.36% to 48.1% within termination clinics. If a higher sensitivity and specificity is assumed to 
indicate a higher accuracy, recruitment setting does not appear to affect accuracy in a consistent manner. 
The test accuracy of the Papanicolaou test was higher when participants were recruited from the antenatal 
clinic, whereas the inverse was true for the DFA (Microtrak) test where test accuracy was higher in the 
abortion clinic setting. 
There were further concerns over a suitable reference standard for detecting Chlamydia. The ideal study 
of test performance would involve comparison with a recognized gold standard. However, in the field of 
Chlamydia research, there is little agreement on a recognized gold standard although it is commonly 
acknowledged that the traditional gold standard of culture does not perform as well as the newer tests [6]. 
Today, few laboratories in the United Kingdom offer culture as a service as they are expensive, labor 
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intensive, and time-consuming. The sensitivity is no more than 75% and is no longer used for 
medicolegal purposes [22]. In nonpregnant populations, NAAT testing has been proven in multiple 
studies to provide superior sensitivity and specificity [23–25] and is now the recommended method of 
diagnosis. One included a study that compared the Gen-Probe PACE 2, a recognized assay for Chlamydia 
testing, to culture revealed a high sensitivity and specificity. Another study that compared PCR to Gen-
Probe PACE 2 found excellent results for PCR with 100.0% sensitivity and 98.3% specificity. However, 
they did not use a commercially available kit, thus diminishing clinical applicability.  
There are a number of commercial NAATs currently available for routine use, those commonly used in 
clinical practice include: Abbott RealTime PCR assay (Abbott Diagnostics), BD ProbeTec ET (SDA, 
Beckton Dickinson), COBAS Taqman PCR assay (Roche Diagnostics), and GenProbe Aptima assay 
(TMA, GenProbe) [22]. However, none of these were used as either an index or a reference test in the 
included studies for this review. Considering also that the most recent included study was published in 
2006, it highlights that research into test accuracy within the asymptomatic pregnant population is out-of-
date and requires updating using NAATs as a reference standard. Recently, an ‘expanded gold-standard’ 
has been identified as Chlamydia diagnosed by two nonculture tests [6,26]. A single, commonly 
acknowledged reference standard in test accuracy studies for Chlamydia will enable useful comparisons 
to be drawn. 
Interpretation 
Currently, one review has addressed the issue of test accuracy in an asymptomatic, young female 
population using meta-analysis and metaregression [6]. It concluded that NAATs used on non-invasive 
samples such as urine were more effective at detecting asymptomatic infection, but acknowledged that 
limited data existed to correlate a positive result with clinical outcome. Another review has qualitatively 
analysed existing POCTs and concluded that Xpert CT/NG, a form of NAAT was the best performing 
test [7,27]. The evidence supporting the use of NAATs in a non-pregnant population is compelling, and 
there is large potential for its applicability to the asymptomatic pregnant population. 
Manuscript submitted to Curr Opin Obstet Gynecol 
The diagnosis of Chlamydia in pregnancy is important, as infection during pregnancy has been shown to 
have four-fold increased risk of preterm labour before 32 weeks’ gestation [28,29]. The availability of a 
simple and affordable treatment for Chlamydia through the administration of antibiotics also makes the 
possibility of reducing preterm labour through treatment of Chlamydia extremely realistic. As such, the 
analysis of the accuracy of available tests would have been instrumental. 
 
CONCLUSION 
This systematic review has identified a gap in current literature for test accuracy studies in an 
asymptomatic pregnant population, particularly in antenatal settings. The evidence underlying the risks of 
chlamydial infection in pregnancy is compelling. Future test accuracy studies for this population studies 
should aim to use a new, universally established reference standard with a specific NAAT or combination 
of NAATs to be considered as options. However, further research should provide more evidence to 
strengthen this claim. 
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Table 1: Characteristics of Included Studies 
Study 
Authors 
and Year 
Location Test used Sample type Reference test Country Setting 
Income 
level 
Asbill 
2000 
Charlotte, 
USA 
Wet Mount Gram stain 
Endocervical 
swab 
Gen-Probe Pace 
2 (Gen Probe 
Inc, San 
Francisco, Calif) 
USA 
Antenatal 
care 
High 
Asbill 
2000 
Charlotte, 
USA 
PCR 
Endocervical 
swab 
Gen-Probe Pace 
2 (Gen Probe 
Inc, San 
Francisco, Calif) 
USA 
Antenatal 
care 
High 
Bohmer 
1999 
Charlotte, 
USA 
Wet Mount Gram stain  
Endocervical 
swab 
Gen-Probe Pace 
2 (Gen Probe 
Inc, San 
Francisco, Calif) 
USA 
Antenatal 
care 
High 
Cornetta 
2006 
Sao Paolo, 
Brazil 
Papanicolau smear 
Endocervical 
swab 
McCoy Cell 
Culture 
Brazil 
Antenatal 
care 
Upper 
Middle 
Thejls 
1995 
Gavle, 
Sweden 
IgA≥8 (MIF) 
Endocervical 
swab 
McCoy Cell 
Culture 
Sweden 
Antenatal 
care 
High 
Thejls 
1995 
Gavle, 
Sweden 
IgG≥8 (MIF) 
Endocervical 
swab 
McCoy Cell 
Culture 
Sweden 
Antenatal 
care 
High 
Thejls 
1995 
Gavle, 
Sweden 
IgG≥16 (MIF) 
Endocervical 
swab 
McCoy Cell 
Culture 
Sweden 
Antenatal 
care 
High 
Bakir 
1989 
Riyadh, 
Saudi 
Arabia 
Chlamydiazyme (Abbott 
Laboratories) 
Endocervical 
swab 
McCoy Cell 
Culture 
Saudi 
Arabia 
Antenatal 
care 
High 
Hosein 
1992 
Florida, USA Gen-Probe PACE 2  
endocervical 
swab 
McCoy Cell 
Culture 
USA 
Antenatal 
care 
High 
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Witkin 
1997  
Jersey, USA 
Chlamydia IgA Rapid 
SeroTest ELISA (Savyon 
Diagnostics) 
Endocervical 
swab 
Amplicor PCR 
(Roche 
Diagnostics) 
USA 
Inner-city 
medical 
centre 
High 
Witkin 
1997  
Jersey, USA 
Chlamydiazyme (Abbott 
Laboratories) 
Endocervical 
swab 
Amplicor PCR 
(Roche 
Diagnostics) 
USA 
Inner-city 
medical 
centre 
High 
Hopwood 
2001 
Merseyside, 
United 
Kingdom 
Clearview chlamydia MF 
(Unipath) 
Endocervical 
swab 
Ligase Chain 
Reaction 
(Abbott 
Laboratories 
LCx system) 
with PCR as 
arbiter (Roche 
COBAS) 
UK 
Termination 
clinic 
High 
Csango 
1988 
Norway & 
Israel 
IgG≥16 (L2 
immunoperoxidase 
assay, IPA 'Ipazyme 
Chlamydia' Savyon 
Diagnostics Ltd, Israel) 
Blood sample 
for index test, 
endocervical 
swab for 
reference 
Cell culture 
Norway 
& Israel 
Termination 
clinic 
High 
Csango 
1988 
Norway & 
Israel 
IgA≥8 (L2 
immunoperoxidase 
assay, IPA 'Ipazyme 
Chlamydia' Savyon 
Diagnostics Ltd, Israel) 
Blood sample 
for index test, 
endocervical 
swab for 
reference 
Cell culture 
Norway 
& Israel 
Termination 
clinic 
High 
Martin 
1995 
Victoria, 
Australia 
PCR  plasmid primers 
Endocervical 
swab 
Culture 
(Pathfinder 
Chlamydia 
Confirmation 
System) 
Australia 
Termination 
clinic 
High 
Spence 
1986 
Maryland, 
USA 
Papanicolau (FAST) 
smear 
Endocervical 
swab 
McCoy Cell 
Culture 
USA 
Termination 
clinic 
High 
Thejls 
1994 
Sweden 
Direct Enzyme 
Immunoassay (EIA) 
(MicroTrak, SYVA, Palo 
Alto, CA) 
Endocervical 
swab 
McCoy Cell 
Culture 
Sweden 
Termination 
clinic 
High 
Thejls 
1994 
Sweden 
Direct 
Immunofluorescence 
Assay (DFA) 
(MicroTrak, SYVA, Palo 
Alto, CA) 
Endocervical 
swab 
McCoy Cell 
Culture 
Sweden 
Termination 
clinic 
High 
Thejls 
1994 
Sweden 
PCR (Ampl-Taq 
Polymerase, Perkin 
Elmer) 
Endocervical 
swab 
McCoy Cell 
Culture 
Sweden 
Termination 
clinic 
High 
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Table 2: Study Quality Assessment using QUADAS-2 tool  
QUADAS Risk of bias  Applicability  
Study ID Sample selection Index test Ref stand Flow and timing Sample selection Index test Ref stand 
Asbill 2000 High Low Low Low Low Low Low 
Bohmer 1999 Unclear Unclear Low Low Low Low Low 
Hopwood 2001 Unclear High Low Low Low Low Low 
Van Dyck 1992 Low Low Low Low Low Low Low 
Cornetta 2006 Low Low Low Low Low Low Low 
Csango 1988 Unclear Low Unclear Low High Low Unclear 
Martin 1995 Unclear Low Low Unclear High Low Low 
Smith 1987 Low Low Low Low Low Low Low 
Spence 1986 Unclear Low Low  High High Unclear Low 
Thejls 1994 Unclear Low Low Low Unclear Low Low 
Thejls 1995 Unclear Low Low Low Unclear Low Low 
Witkin 1997  Unclear Unclear Low Low Unclear Unclear Low 
Bakir 1989 Unclear Low Low Low Low Low Low 
Hosein 1992 Low Low Low Low Low Low Low 
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